We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

New Cellular Reporter Technologies using X-MAN™ Cell Models Poster

SEARCH POSTERS

Abstract

Paul Morrill1, Chris Torrance1, Christine Schofield1, Holly Astley1, Sue Rigby1, Tom Henley1, Claire Mahoney1, Paul Gonzales2, Bernardo Chavira2, Mei Cong3, Danette Daniels3, Hélène Benink3, Nancy Murphy3, Jeff Kelly3
1Horizon Discovery Ltd, Cambridge, UK, 2TGen Drug Development, Scottsdale, Arizona, USA, 3Promega Corporation, Madison, Wisconsin, USA

X‐MAN™ (gene‐X Mutant And Normal) cell lines provide genetically defined, patient‐relevant, predictive in vitro models of genetic disease. We are further extending their application within targeted drug discovery with the development of new reporter disease models using our GENESIS™ gene engineering technology (Figure 1). These models combine X‐MAN™ cell lines with the endogenous gene reporting capabilities in the form of NanoLuc™ luciferase and HaloTag® reporter technologies.

Document Icon Download the poster PDF (1213kb)

  • Part# PS142
  • Printed in USA.
Choose your country

Americas

Brazil
Canada
United States

Pacific Asia

Australia
India
Japan
Korea, Republic of
Singapore

Europe

Austria
Belgium
Denmark
Estonia
Finland
France
Germany
Iceland
Italy
Luxembourg
Netherlands
Norway
Poland
Spain
Sweden
Switzerland
United Kingdom